Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies.

Categoria Primary study
GiornaleEndocrine Abstracts
Year 2010
Loading references information
Questo articolo non ha abstract
Epistemonikos ID: 3535d0460947655b843cdb24060ede5d7cdd1ede
First added on: May 08, 2020